$PSID Positive ID Corp. Climbs 178% On NEWS And Late Day Surge

PositiveID’s ExcitePCR Subsidiary to Hold Press Conference Announcing Lawrence Livermore National Report on its FireflyDX

Sep 12, 2017

DELRAY BEACH, Fla., Sept. 12, 2017 (GLOBE NEWSWIRE) — PositiveID Corporation’s (OTCQB:PSID) ExcitePCR subsidiary today announced that it will hold a Press Conference at 10 a.m. on Monday, September 18th at the National Press Club in Washington, D.C., to disclose details from a new report produced by Lawrence Livermore National Laboratory for ExcitePCR on the FireflyDX pathogen detection system.

During the Press Conference, ExcitePCR will summarize its multiyear history in designing, developing and producing automated biohazard detection for U.S. governmental agencies and military organizations, as well as showcase its forthcoming FireflyDX-Portable™ pathogen detection system and select details from the report produced by LLNL for the company.


An ExcitePCR Press Conference on Monday, September 18, 2017, from 10-11 a.m. (ET) will disclose details from a Lawrence Livermore National Laboratory Report prepared for the company that states that ExcitePCR’s FireflyDX automated pathogen detection technologies have no known direct competition. {NOTE: ExcitePCR will release its own Executive Summary of the LLNL Report during the Press Conference.}

During the press conference, ExcitePCR will also provide additional details about its lightweight, bookbag-sized FireflyDX-Portable, a realtime pathogen detection system designed to enable first responders, medical professionals and food safety workers to accurately obtain on-site results anywhere in the world in less than 30 minutes, including sample preparation time.


The ExcitePCR Press Conference will be held at the National Press Club in Washington, D.C. at 529 14th Street NW, Washington, D.C.


The ExcitePCR Press Conference will be held from 10-11 a.m. (ET) on Monday, September 18, 2017.


Representing ExcitePCR at the press conference will be

Lyle Probst, President, CEO, and Founder;
Kimothy Smith, Ph.D., Chief Science Officer; and
David Politis, Chief Marketing & Sales Officer.

Journalists and Analysts interested in and/or who cover/report on infectious diseases, pandemics, epidemics, biohazards, pathogenic threats, First Responders, Homeland Security, the military, and/or Polymerase Chain Reaction (PCR), as well as those who follow or have reported on such firms as Theranos, bioMerieux, Thermo Fisher Scientific, are those most likely to appreciate the information that will be shared during ExcitePCR’s September 18th Press Conference.


Including its predecessor companies, ExcitePCR has received over $35 million since 2004 from the U.S. Department of Homeland Security (DHS) and other U.S. governmental entities to design, develop and produce rapid pathogen detection solutions. This foundational work has allowed ExcitePCR to produce significant breakthroughs in the world of PCR-based solutions for rapidly and accurately identifying the presence of countless biological threats anywhere in the world, including the typically time-consuming act of sample preparation, all within 30 minutes or less. ExcitePCR has now begun work to commercialize its FireflyDX technologies that Lawrence Livermore National Laboratory says have no known competition.


Following the Press Conference, ExcitePCR’s CEO, Lyle Probst, will participate in a prestigious, three-person Panel Discussion about current and future advancements in pathogen detection systems hosted by the National Academies of Science, Engineering, and Medicine (NAS). This panel discussion is part of a two-day, BioWatch Workshop on “Strategies for Effective Biological Detection Systems” hosted by the NAS. Interested parties can learn more about this Panel Discussion here.

About PositiveID Corporation
PositiveID Corporation is a holding company focused on life sciences, diagnostics, mobile laboratories, and medical devices. PositiveID’s ExcitePCR subsidiary is developing the FireflyDX family of pathogen detection systems, portable devices offering rapid sample-to-result detection in less than 30 minutes using real-time polymerase chain reaction chemistry. PositiveID’s E-N-G Mobile Systems™ subsidiary is a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. PositiveID’s Thermomedics™ subsidiary markets the FDA-cleared Caregiver® non-contact thermometer for clinical use. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

On August 24, 2017, PositiveID Corporation and its wholly-owned subsidiary PositiveID Diagnostics, Inc. (collectively, the “Seller”), entered into an Asset Purchase Agreement (“APA”) with ExcitePCR Corporation. Pursuant to the APA, at closing, the Seller will sell and deliver to ExcitePCR all assets used in connection with the operation of the FireflyDX technology. For more information on the APA, please read PositiveID’s Form 8-K filed on August 28, 2017, which can be found here.

Be the first to comment

Leave a Reply

Your email address will not be published.